Muscarinic Receptor Antagonism and TRPM3 Activation as Stimulators of Mitochondrial Function and Axonal Repair in Diabetic Sensorimotor Polyneuropathy.
Level 5 - mechanism / opinion, no new human data
Narrative review of mechanistic and preclinical pathways without original human data or systematic review methodology.
PubMed 40806522 · doi:10.3390/ijms26157393
What was done
This narrative review synthesized literature on mitochondrial dysfunction and calcium dyshomeostasis in diabetic sensorimotor polyneuropathy (DSPN). It evaluated mechanistic and preclinical evidence surrounding muscarinic acetylcholine type 1 receptor (M1R) antagonism (notably pirenzepine) and transient receptor potential melastatin-3 (TRPM3) activation as nerve-repair pathways.
What was found
The abstract reports no empirical numbers or effect estimates. It qualitatively describes that M1R antagonism restores mitochondrial function and axon repair in DSPN, chemotherapy-induced peripheral neuropathy, and HIV neuropathy, while downstream TRPM3 activation enhances mitochondrial calcium uptake, bioenergetics, and axonal sprouting.
Why it matters
DSPN lacks disease-modifying therapies that reverse nerve damage. Targeting M1R and TRPM3 signaling represents a potential shift from symptomatic control toward bioenergetic restoration and axonal regeneration.
Limits
This is a narrative review with no new human data, sample size details, or systematic synthesis. The reported mechanisms rely primarily on preclinical models, and clinical efficacy in humans is not established in the abstract.
Cited by
- supports Targeting mitochondria to increase their function can overcome the neurodegenerative process in peripheral neuropathy.